Abstract

Provided in the present invention are a bispecific antibody that specifically binds to PD-L1 and CD40, and the use thereof. The bispecific antibody comprises: (1) a PD-L1-binding domain, which is VHH, wherein sequences of CDR1-3 in the VHH are as set forth in SEQ ID NOs: 2-4, respectively; and (2) a CD40-binding domain, comprising VH and VL, wherein sequences of HCDR1-3 in the VH are as set forth in SEQ ID NOs: 21-23, respectively, and sequences of LCDR1-3 in the VL are as set forth in SEQ ID NOs: 18-20, respectively.

[No Suitable Figure]